Practitioners opted to target only the injectable dosage forms of olanzapine and benzodiazepines. This decision was made based on the more pronounced pharmacokinetic properties of the parenteral ...

Global clinical nutrition market will reach $107.65 billion by 2032, growing by 8.2% annually over 2022-2032. The growth is driven by the increasing incidence of malnutrition, the rising prevalence of ...

In this podcast episode, we discuss trends in dosage forms, specifically oral solid dosage ... of and the progress made so far by the biopharma industry toward non-parenteral means of delivering ...

and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS ...

A consortium of investors led by Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital and Pharmascience ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...

KBC Group NV lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 43.2% during the 4th quarter, Holdings Channel reports. The fund owned 37,163 shares of the ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...

Also, the researchers noted in their New England Journal of Medicine paper, "the lower risk of gastrointestinal bleeding with a parenteral anticoagulant ... to the inactive form of factor XI ...